Grass pollen allergy immunotherapy - Bial

Drug Profile

Grass pollen allergy immunotherapy - Bial

Alternative Names: Allergovac depot Olea; Allergovac grass pollen; Allergovac grass pollen depot; Allergovac Poliplus; BIA 14-2964; Olea europaea extract - Bial

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bial
  • Developer BIAL; ROXALL Medizin GmbH
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 15 Jun 2017 Bial completes a phase II trial for Allergic rhinoconjunctivitis (sensitised to Olea europaea) in Spain (SC) (EudraCT2014-001569-29)
  • 01 Jun 2016 Bial completes a phase I trial for Allergic rhinoconjunctivitis in Spain (SC) (NCT02849249)
  • 01 May 2016 Bial completes a phase II trial for Allergic rhinoconjunctivities (sensitised to Parietaria judaica) in Spain (EudraCT2014-001459-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top